Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Survival Curves01:18

Survival Curves

Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to Comment on "Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective".

PharmacoEconomics·2025
Same author

Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective.

PharmacoEconomics·2025
Same author

Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.

Drugs - real world outcomes·2022
Same author

Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.

PloS one·2022
Same author

Impact of hospitalisation on health-related quality of life in patients with chronic heart failure.

Health and quality of life outcomes·2020
Same author

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.

The European journal of health economics : HEPAC : health economics in prevention and care·2019

Related Experiment Video

Updated: May 15, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Cost-effectiveness acceptability curves revisited.

Maiwenn J Al1

  • 1Institute for Medical Technology Assessment, Erasmus University, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands. al@bmg.eur.nl

Pharmacoeconomics
|January 19, 2013
PubMed
Summary

The cost-effectiveness acceptability curve (CEAC) helps quantify uncertainty around incremental cost-effectiveness ratios (ICERs). Despite limitations, CEAC remains valuable when used correctly with other tools for health economic evaluations.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Related Experiment Videos

Last Updated: May 15, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Area of Science:

  • Health Economics
  • Decision Analysis
  • Biostatistics

Background:

  • The cost-effectiveness acceptability curve (CEAC) was introduced in 1994.
  • Its application in assessing uncertainty around incremental cost-effectiveness ratios (ICERs) has grown significantly.

Purpose of the Study:

  • To explain the construction and interpretation of CEACs.
  • To review the advantages and limitations of CEACs.
  • To clarify the appropriate use of CEACs in health economic evaluations.

Main Methods:

  • Explanation of CEAC construction in modeling and trial-based cost-effectiveness (CE) studies.
  • Review of CEAC advantages and limitations.
  • Discussion on interpreting CEACs correctly, not as decision rules.

Main Results:

  • CEACs are valuable for describing and quantifying uncertainty around ICERs.
  • Perceived limitations often stem from misinterpreting CEACs as decision rules.
  • CEACs are most effective when used alongside other tools like cost-effectiveness (CE) plane plots and value-of-information analysis.

Conclusions:

  • The CEAC is a robust tool for uncertainty analysis in cost-effectiveness studies.
  • Proper interpretation is key to leveraging CEACs effectively.
  • Combining CEACs with other methods enhances their utility in health economic decision-making.